Efficacy and safety of an mRNA seasonal influenza vaccine in adults (Registro nro. 22927)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03604nam a2200349 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260903143758.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Leroux-Roels, Isabel |
| Rol del Autor | Autor |
| 9 (RLIN) | 54553 |
| 245 ## - Titulo | |
| Titulo | Efficacy and safety of an mRNA seasonal influenza vaccine in adults |
| 300 ## - Páginas | |
| Paginación | páginas: 1803-1813 |
| 520 ## - Resumen | |
| Resumen | Background: Seasonal influenza causes substantial illness and death in adults 50 years of age or older, even with current vaccines. An investigational messenger RNA (mRNA)–based vaccine called mRNA-1010 encodes hemagglutinin glycoproteins from World Health Organization–recommended influenza strains. Methods: In this phase 3, double-blind, active-controlled trial, we randomly assigned adults 50 years of age or older to receive trivalent mRNA-1010 (37.5 μg, which includes 12.5 μg of each strain) or a licensed standard-dose comparator. The primary efficacy end point was relative vaccine efficacy against reverse-transcriptase–polymerase-chain-reaction (RT-PCR)–confirmed, protocol-defined influenza-like illness caused by influenza A or B, from at least 14 days after vaccination through the end of the influenza season. Hypothesis testing was conducted hierarchically to assess noninferiority (lower boundary of the 95% confidence interval [CI], >−10%), superiority (lower boundary of the 95% CI, >0%), and a higher level of superiority (lower boundary of the 95% CI, >9.1%). Results: A total of 40,703 participants received mRNA-1010 (20,350 participants) or the standard-dose comparator (20,353 participants); the median follow-up was 181 days (range, 1 to 227). RT-PCR–confirmed, protocol-defined influenza-like illness was observed in 411 of 20,179 recipients of mRNA-1010 (2.0%) and 557 of 20,124 recipients of the standard-dose comparator (2.8%), which corresponds to a relative vaccine efficacy of 26.6% (95% CI, 16.7 to 35.4), thereby meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions were more frequent with mRNA-1010 than with the standard-dose comparator (injection-site pain in 65.8% vs. 29.8%, fatigue in 45.1% vs. 20.3%, headache in 37.8% vs. 18.0%, and myalgia in 35.4% vs. 11.6%); most reactions were mild to moderate and transient. Serious adverse events were reported in 2.2% of the recipients of mRNA-1010 (with three events considered by the investigator to be vaccine-related) and in 1.9% of the recipients of the standard-dose comparator (with two events considered by the investigator to be vaccine-related). Conclusions: In this trial, mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR–confirmed, protocol-defined influenza-like illness in adults 50 years of age or older. Solicited adverse reactions were more frequent with mRNA-1010. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | GERIATRÍA |
| 9 (RLIN) | 1852 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENVEJECIMIENTO GENERAL |
| 9 (RLIN) | 54554 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | MEDICINA CLÍNICA HOSPITALARIA |
| 9 (RLIN) | 53754 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDADES INFECCIOSAS GENERALES |
| 9 (RLIN) | 54087 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | INFLUENZA |
| 9 (RLIN) | 54088 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | INFECCIONES VIRALES |
| 9 (RLIN) | 53766 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TERAPIAS DE ARN |
| 9 (RLIN) | 54555 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | VACUNAS |
| 9 (RLIN) | 8158 |
| 700 ## - Autor Personal | |
| Autor Personal | Huang, Grace |
| 9 (RLIN) | 54556 |
| 700 ## - Autor Personal | |
| Autor Personal | Ferguson, Murdo |
| 9 (RLIN) | 54557 |
| 700 ## - Autor Personal | |
| Autor Personal | Kohli, Anita |
| 9 (RLIN) | 54558 |
| 700 ## - Autor Personal | |
| Autor Personal | Clark, Rebecca |
| 9 (RLIN) | 54559 |
| 700 ## - Autor Personal | |
| Autor Personal | Bickel, Markus |
| 9 (RLIN) | 54560 |
| 700 ## - Autor Personal | |
| Autor Personal | Soens, Mieke |
| 9 (RLIN) | 54561 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22676 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM015 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-31 |
| Catalogador | sqb |
No hay ítems disponibles.